Study of Light Treatment and Laser Treatment for Melasma

Northwestern University17 enrolled

Overview

The purpose of this study is to determine the efficacy of light treatment and laser treatment for melasma. These treatment options have not been thoroughly explored in the treatment of melasma. By studying the effect of different treatments, a better treatment plan may be developed for people with melasma.

The objective of this study is to determine the efficacy of light treatment and laser treatment for melasma. These treatment options have not been thoroughly explored in the treatment of melasma. By studying the effect of different treatments, a better treatment plan may be developed for people with melasma.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Melasma

Interventions

Light TreatmentPROCEDURE

Light treatment applied to half of the face at each study visit

Laser TreatmentPROCEDURE

Laser treatment applied to half of the face at each study visit

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of melasma lesion measuring at least 4 square centimeters. * Age 18-75 years. * Good health. * Willingness and ability to understand and provide informed consent for participation in the study. * Ability to communicate with the investigator. * Must be willing to forgo other treatment options for melasma during the course of the study. Exclusion Criteria: * Inability to understand the protocol or to give informed consent. * Mental illness. * Under 18 years of age and over 75 years of age. * Laser treatment in the last 6 months before enrollment. * Isotretinoin within the past year. * Lidocaine allergy. * History of herpes simplex viral infection. * Concurrent active disease to facial area (i.e acne). * Bleeding disorder. * History of abnormal wound healing. * History of abnormal scarring.

Locations (1)

Northwestern University Feinberg School of Medicine, Department of Dermatology

Chicago, Illinois, United States

Outcomes

Primary Outcomes

Melasma Area and Severity Index

Time frame: 20 weeks

Secondary Outcomes

Safety

Time frame: 20 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.